Gastro-oesophageal reflux disease (GERD) is a common disorder in adults and children.
The global prevalence of GERD is high and increasing. Non-erosive reflux disease is the …

Background Potassium‐competitive acid blockers (P‐CABs) are a novel group of acid‐
suppressing medicines for the management of acid‐related disorders. Aims To review …

Potassium-competitive acid blocker (P-CAB) is a class of drug that competitively blocks the
potassium-binding site of H+, K+-adenosine triphosphate (ATP) ase. Although the history of …

Key Clinical Points Gastroesophageal Reflux Disease Patients with heartburn and
symptoms such as dysphagia, odynophagia, weight loss, anorexia, gastrointestinal …

In Japan, with the increasing prevalence of gastroesophageal reflux disease (GERD) and
growing public interest, the Japanese Society of Gastroenterology issued Evidence-based …

Background Tegoprazan is a novel potassium‐competitive acid blocker that has a fast onset
of action and can control gastric pH for a prolonged period, which could offer clinical benefit …

Background Gastroesophageal reflux disease (GERD) is a common disorder, and is
typically treated with proton-pump inhibitors (PPIs) as the recommended first-line therapy …

Background Tegoprazan is a novel, fast‐and long‐acting potassium‐competitive acid
blocker that suppresses gastric acid secretion, which could benefit patients with non‐erosive …

Description The purpose of this American Gastroenterological Association (AGA) Institute
Clinical Practice Update (CPU) is to summarize the available evidence and offer expert Best …

Abstract Purpose of Review Despite the many areas of unmet needs in gastroesophageal
reflux disease (GERD), proton pump inhibitors (PPIs) remain the cornerstone of medical …